Awareness of Rural Youth towards Disaster Management: A Gender Disintegrated Study

ABSTRAC

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm : conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARM agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARM agonist safely reduces residual cardiovascular risk.Peer reviewe

Extent of Awareness and Various Challenges Faced by the Rural People Due to Pandemic of COVID-19

COVID-19 is an infectious disease which caused severe pandemic to the whole world. Due to its effect of various agricultural sectors such as crop, livestock and fishery have been smash hard by pandemic. The study was conducted to get perception of extent of awareness and its effect due to pandemic of COVID-19 by the rural people in Cooch Behar district of West Bengal. There were 80 respondents from four villages who experienced the negative impact of lockdown due to COVID-19 were selected for the study. The data were collected through well-structured interview schedule with the help of online google form as well as verbal communication in mobile phone. Collected data were compiled and analyzed with simple statistical tools to draw a specific conclusion. The results show that 41.25 per cent of the respondent had high level of awareness on COVID-19 followed by 20.0 per cent had lower level of awareness on corona virus disease. The finding also said that 82.50 per cent of the respondent had faced challenges of lack of opportunities for earning money followed by 72.50 per cent had scarcity of food materials or insufficient of food items in the locality during pandemic of COVID-19. Due to lockdown, the movement of agriculture produces from its place of production to the ultimate consumer has been also affected. It is suggested that some more specific and need based income generating measure is required to taken by the various existing government and non-government organization to reduce the pandemic situation among rural communities

Silver hull buckwheat (Fagopyrum esculentum Moench) is a part of nature that offers best health and honour

The gluten-free pseudocereal Fagopyrum esculentum Moench (Silver hull buckwheat) belongs to the Polygonaceae family, which has a long history of both edible and medicinal use. It's a highly nutritious food ingredient that's been shown to have a variety of health benefits. Plasma cholesterol levels are lowered, neuroprotection is given, anticancer, anti-inflammatory, antidiabetic effects are provided, and hypertension conditions are improved thanks to Silver hull buckwheat. It has also been stated to have prebiotic and antioxidant properties. The aim of this review was to include an up-to-date and detailed study of F. esculentum. Furthermore, the potential for future research was addressed. Flavonoids, phenolics, fagopyritols, triterpenoids, hormones, and fatty acids are among the various compounds derived from F. esculentum. The main active ingredients were believed to be flavonoids and phenolic compounds. All of the information presented leads us to believe that Silver hull buckwheat has a strong medicinal potential. However, further research is needed to better understand its bioactive constituents, their structural functions, and molecular mechanisms underlying

Whole-exome sequencing and variant spectrum in children with suspected inherited renal tubular disorder: the East India Tubulopathy Gene Study

Background: Inherited tubulopathies are a heterogeneous group of genetic disorders making whole-exome sequencing (WES) the preferred diagnostic methodology. Methods: This was a multicenter descriptive study wherein children (< 18 years) with clinically suspected tubular disorders were recruited for molecular testing through WES. Multiplex ligation-dependent probe amplification (MLPA) and Sanger sequencing were done when required. Variants were classified as per American College of Medical Genetics 2015 guidelines and pathogenic (P)/likely pathogenic (LP) variants were considered causative. Results: There were 77 index cases (male =73%). Median age at diagnosis was 48 months (IQR 18.5 to 108 months). At recruitment, the number of children in each clinical group was as follows: distal renal tubular acidosis (dRTA) = 25; Bartter syndrome = 18; isolated hypophosphatemic rickets (HP) = 6; proximal tubular dysfunction (pTD) = 12; nephrogenic diabetes insipidus (NDI) = 6; kidney stone/nephrocalcinosis (NC) = 6; others = 4. We detected 55 (24 novel) P/LP variants, providing genetic diagnoses in 54 children (70%). The diagnostic yield of WES was highest for NDI (100%), followed by HP (83%; all X-linked HP), Bartter syndrome (78%), pTD (75%), dRTA (64%), and NC (33%). Molecular testing had a definite impact on clinical management in 24 (31%) children. This included revising clinical diagnosis among 14 children (26% of those with a confirmed genetic diagnosis and 18% of the overall cohort), detection of previously unrecognized co-morbidities among 8 children (sensorineural deafness n = 5, hemolytic anemia n = 2, and dental changes n = 1) and facilitating specific medical treatment for 7 children (primary hyperoxaluria n = 1, cystinosis n = 4, tyrosinemia n = 2). Conclusion: WES is a powerful tool in the diagnosis and management of children with inherited tubulopathies in the Indian population. Graphical abstract : A higher resolution version of the Graphical abstract is available as Supplementary information[Figure not available: see fulltext.

Application of innovation platforms to catalyse adoption of conservation agriculture practices in South Asia

Conservation agriculture-based sustainable intensification (CASI) is a package of practices that could improve the sustainability of smallholder farm productivity and profitability. However, existing extension systems are unable to facilitate widespread adoption to have the impact necessary to meet food security and livelihood requirements. This paper examines the utility of ‘Innovation Platforms’ (IPs) as a tool to catalyse adoption of CASI for smallholder farmers in South Asia and generate opportunities for rural micro-entrepreneurship in areas with high rates of poverty, small farm sizes and complex labour markets. We established 37 village-level and five District-level IPs across the Eastern Gangetic Plains of Nepal, Bangladesh, and India. IPs allowed widespread uptake of CASI with benefits to smallholder farmers, input and output suppliers, and enabled extension systems to be more efficient. There was variability across locations with different modes of IPs established, building on existing farmer or community youth groups, and enabling micro-entrepreneur business opportunities. IPs were effective in developing trust in communities, among stakeholders, empowering rural youth and women through direct engagement. Ensuring strong ownership was key. Further work is needed to provide opportunities for high-level policy support to assist IPs to have a wider impact in supporting large-scale adoption of CASI

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels. METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes. RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. The median follow-up was 3.4 years. As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point event occurred in 572 patients in the pemafibrate group and in 560 of those in the placebo group (hazard ratio, 1.03; 95% confidence interval, 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup. The overall incidence of serious adverse events did not differ significantly between the groups, but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism and a lower incidence of nonalcoholic fatty liver disease. CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.)